Bruker Corporation (NASDAQ:BRKR) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Analyst consensus: Bruker has an average recommendation of "Hold" from 15 brokerages (2 sell, 5 hold, 7 buy, 1 strong buy) with a mean 12‑month price target of $49.38.
• In the most recent quarter Bruker missed EPS at $0.59 versus $0.65 expected while revenue of $977.2M topped estimates, and management set FY2026 EPS guidance of $2.10–$2.15 compared with analysts' forecast of $2.69.
• The company pays a quarterly dividend of $0.05 (0.5% yield) despite a negative payout ratio; insiders recently sold shares (VP sold 2,000 at $39.90) and institutional investors own roughly 79.5% of the stock.

Bruker Corporation (NASDAQ:BRKR - Get Free Report) has received an average recommendation of "Hold" from the fifteen research firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, five have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $49.3846.

BRKR has been the subject of several recent research reports. Jefferies Financial Group set a $50.00 price target on Bruker in a research report on Thursday, February 12th. Citigroup decreased their price objective on Bruker from $53.00 to $40.00 and set a "neutral" rating on the stock in a research note on Friday, February 13th. TD Cowen upgraded Bruker to a "hold" rating in a research report on Monday. Guggenheim cut their target price on shares of Bruker from $58.00 to $50.00 and set a "buy" rating for the company in a research note on Monday, March 30th. Finally, The Goldman Sachs Group reduced their target price on shares of Bruker from $40.00 to $35.00 and set a "sell" rating on the stock in a report on Friday, February 13th.

Bruker Stock Performance

Shares of BRKR opened at $38.94 on Friday. Bruker has a 12-month low of $28.53 and a 12-month high of $56.22. The stock has a market cap of $5.93 billion, a P/E ratio of -259.60, a PEG ratio of 2.36 and a beta of 1.20. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. The company has a 50-day moving average of $37.47 and a two-hundred day moving average of $41.68.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing analysts' consensus estimates of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The business had revenue of $977.20 million for the quarter, compared to analysts' expectations of $964.61 million. During the same period last year, the business earned $0.76 earnings per share. The company's revenue for the quarter was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts predict that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 23rd were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, March 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Bruker's dividend payout ratio is presently -133.33%.

Insider Transactions at Bruker

In related news, VP Mark Munch sold 2,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $39.90, for a total transaction of $79,800.00. Following the sale, the vice president owned 128,443 shares in the company, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 27.30% of the company's stock.

Institutional Investors Weigh In On Bruker

Hedge funds have recently made changes to their positions in the business. Rockefeller Capital Management L.P. increased its stake in Bruker by 741.9% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,522 shares of the medical research company's stock valued at $449,000 after purchasing an additional 8,391 shares during the last quarter. Mengis Capital Management Inc. boosted its stake in Bruker by 2.0% in the 4th quarter. Mengis Capital Management Inc. now owns 57,220 shares of the medical research company's stock worth $2,696,000 after buying an additional 1,135 shares during the last quarter. Pacer Advisors Inc. boosted its stake in Bruker by 42.8% in the 4th quarter. Pacer Advisors Inc. now owns 20,822 shares of the medical research company's stock worth $981,000 after buying an additional 6,242 shares during the last quarter. Alberta Investment Management Corp purchased a new stake in Bruker in the 4th quarter valued at about $1,748,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Bruker during the 4th quarter valued at about $266,000. Institutional investors and hedge funds own 79.52% of the company's stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.